The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
ASX:MVP's 9-Day RSI is ranked better than 57.31% of 1047
companies
in the Drug Manufacturers industry
Industry Median: 50.66
vs ASX:MVP: 48.67
Medical Developments International (ASX:MVP) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Medical Developments International 9-Day RSI Related Terms
ASX:MVP vs ZTS, UTHR: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Developments International 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Medical Developments International's 9-Day RSI falls into.
Medical Developments International (ASX:MVP) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International (ASX:MVP) has a 9-Day RSI of 48.67 as of Jul. 12, 2026. According to the industry distribution chart, Medical Developments International ranks #447 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 42.7%.
Is Medical Developments International's 9-Day RSI too high?
Medical Developments International's current 9-Day RSI is 48.67. The Drug Manufacturers industry median 9-Day RSI is 50.66. Medical Developments International's value of 48.67 is 3.9% below this industry median. Based on the distribution chart, Medical Developments International ranks #447 out of 1047 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Medical Developments International has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's 9-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #447 out of 1047 companies for 9-Day RSI. This puts Medical Developments International in the upper half of its industry. The industry median 9-Day RSI is 50.66. Medical Developments International's value of 48.67 is 3.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 50.66, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current 9-Day RSI of 48.67 is 3.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 50.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current 9-Day RSI is 48.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (ASX:MVP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.65, compared to a current price of A$0.41 — trading 37.7% below its estimated fair value. The current 9-Day RSI is 48.67 and 3.9% below the Drug Manufacturers industry median of 50.66. Medical Developments International's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Medical Developments International (ASX:MVP), the current 9-Day RSI is 48.67 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (ASX:MVP) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of A$0.41 is trading 37.7% below its estimated GF Value™ of A$0.65.
GuruFocus considers Medical Developments International to be Significantly Undervalued.
Key valuation signals for ASX:MVP:
9-Day RSI: 48.67
GF Value™: A$0.65 vs. price of A$0.41 (37.7% below fair value)
Industry Position: 3.9% below the Drug Manufacturers median (#447 of 1047)
No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Business Description
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
55GF Score
Get the complete analysis for ASX:MVP
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MVP has been successfully added to your 